Design of phase II oncology trials evaluating combinations of experimental agents
Design of phase II oncology trials evaluating combinations of experimental agents
Abstract We consider the design of phase II trials evaluating combinations of experimental therapies. In the modern era, many immunotherapy and targeted therapy regimens are being developed as combination regimens, including combinations consisting only of experimental agents. In some clinical or drug development scenarios, it may be difficult to isolate …